CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of CD20 to construct vaccines for B-cell-related disorders. The immunogenicity of the vaccines was tested in BALB/c mice. Results of this study suggest that the mimotope may be a useful tool for the construction of a functional vaccine to treat B cell-related disorders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/092986607780989958 | DOI Listing |
Publication Analysis
Top Keywords
development mimotope-based
4
mimotope-based vaccine
4
vaccine cd20
4
cd20 antigen
4
antigen cd20
4
cd20 b-cell-specific
4
b-cell-specific protein
4
protein primary
4
primary target
4
target immunotherapy
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!